Variability and Risks of Drug Exposure (DRIVE)

Led by Bruno Laviolle, the DRIVE team focuses on assessing the benefits and risks of drug exposure in vulnerable populations (children, the elderly or patients with chronic diseases) whose characteristics are poorly taken into account in clinical studies that generally enroll selected patients.
Benefits and risks of drug exposure

Mission and Research Domains

The DRIVE team led by Bruno Laviolle brings together members of the pharmacokinetic/pharmacodynamic modeling group (INSERM 1414 Clinical Investigation Center), led by Emmanuelle Comets, INSERM researcher, members of the REPERES (EA 7449) research teams, from the University of Rennes and the EHESP School of Public Health, directed by Emmanuel Oger, professor of pharmacology; and members of the Reproducibility In Therapeutic Research (ReITheR) project funded by the ANR, led by Florian Naudet, professor of therapeutics (
The efficacy and safety of drugs depend on the variability of patient response which is closely related to individual cofactors that can alter pharmacokinetics (PK) and/or pharmacodynamics (PD). This variability can be measured by studies conducted specifically for this purpose. Its consequences can be assessed on a large scale and in real life using meta-analyses, pharmacoepidemiological studies and, more recently, big data-based approaches using for example national health databases (SNDS) and data sharing platforms.
The team develops studies using modeling approaches to better characterize the effects and risks of drug exposure for vulnerable individuals or populations (childhood, the elderly, and chronic diseases) through two complementary aspects.